Cardinal Health Faces Overvaluation Pressure Despite Exceptional Returns

Key Facts

1Cardinal Health (CAH) has delivered a 365.1% total return over the past five years, including 46.0% in the last year.

2The stock trades at a P/E ratio of 35.2x, exceeding the industry average of 24.9x and an estimated fair P/E of 29.2x.

Amid a period of strong execution in the specialty healthcare sector, a recent analysis indicates that Cardinal Health (CAH) has delivered an exceptional 365.1% total return over the past five years, including a 46.0% gain in the last year. While these figures underscore robust investor enthusiasm, the stock currently trades at a P/E ratio of 35.2x. This valuation significantly exceeds the industry average of 24.9x and the estimated fair P/E of 29.2x, suggesting that current pricing reflects high future expectations.

Contextualizing this with industry peers, McKesson (MCK) trades at a P/E ratio of approximately 28.5x per market data, positioning CAH at a relative premium. Analysts have noted that pharmaceutical distribution margins remain sensitive to regulatory shifts, meaning the current valuation leaves little margin for error if the company fails to outperform the high growth expectations already baked into its share price.

Regarding recent price action, CAH closed at $233.66 (close July 13, 2026), having traded between a day low of $233.15 and a high of $237.38. With no major healthcare-specific catalysts in the immediate upcoming calendar, traders are closely watching the $233 support level to determine if the stock can maintain its upward momentum despite the perceived overvaluation risks.